Resveratrol inhibits growth of experimental abdominal aortic aneurysm associated with upregulation of angiotensin-converting enzyme 2

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 11, 2017, Pages 2195-2203

  Moran, Corey S ^a   Biros, Erik ^a   Krishna, Smriti M ^a   Wang, Yutang ^b   Tikellis, Chris ^c   Morton, Susan K ^a   Moxon, Joseph V ^a   Cooper, Mark E ^c   Norman, Paul E ^d   Burrell, Louise M ^e   Thomas, Merlin C ^c   Golledge, Jonathan ^a,f  

^a JAMES COOK UNIVERSITY   (Australia)

^b UNIVERSITY OF BALLARAT   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Abdominal aortic aneurysm; Angiotensin II; Animal model cardiovascular disease; Humans; Mice

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; CD11B ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; ELASTIN; FIBRONECTIN; GELATINASE A; GELATINASE B; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; NUCLEAR FACTOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN B CELL 1; OSTEOPONTIN; OSTEOPROTEGERIN; PROTEIN KINASE B; PROTEIN LYSINE 6 OXIDASE; RESVERATROL; SIRTUIN 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; APOLIPOPROTEIN E; AUTACOID; DIPEPTIDYL CARBOXYPEPTIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NFKB1 PROTEIN, MOUSE; SIRT1 PROTEIN, MOUSE; STILBENE DERIVATIVE;

ABDOMINAL AORTIC ANEURYSM; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTIC RUPTURE; AORTIC SMOOTH MUSCLE CELL; AORTIC TISSUE; ARTICLE; CONTROLLED STUDY; CPG ISLAND; DOWN REGULATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEFICIENCY; ENZYME PHOSPHORYLATION; EXPERIMENTAL ANEURYSM; FEMALE; GENE DELETION; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; ORGAN DONOR; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION; ABDOMINAL AORTA; ANIMAL; AORTIC ANEURYSM, ABDOMINAL; BIOSYNTHESIS; CELL CULTURE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYME INDUCTION; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; KNOCKOUT MOUSE; LESIONS AND DEFECTS; LIPID DIET; METABOLISM; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; SMOOTH MUSCLE CELL; TIME FACTOR; VASCULAR SMOOTH MUSCLE;

ANGIOTENSIN II; ANIMALS; AORTA, ABDOMINAL; AORTIC ANEURYSM, ABDOMINAL; AORTIC RUPTURE; APOLIPOPROTEINS E; CELLS, CULTURED; DIET, HIGH-FAT; DILATATION, PATHOLOGIC; DISEASE MODELS, ANIMAL; ENZYME INDUCTION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B P50 SUBUNIT; PEPTIDYL-DIPEPTIDASE A; PHENOTYPE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIRTUIN 1; STILBENES; TIME FACTORS;

EID: 85032912187     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.310129     Document Type: Article

References (54)

1. Sampson UK, Norman PE, Fowkes FG, Aboyans V, Yanna Song, Harrell FE Jr, Forouzanfar MH, Naghavi M, Denenberg JO, McDermott MM, Criqui MH, Mensah GA, Ezzati M, Murray C. Global and regional burden of aortic dissection and aneurysms: Mortality trends in 21 world regions, 1990 to 2010. Glob Heart. 2014;9:171-180.e10. doi: 10.1016/j.gheart.2013.12.010.
2. Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis. 2011;217:57-63. doi: 10.1016/j.atherosclerosis.2011.03.006.
3. Rughani G, Robertson L, Clarke M. Medical treatment for small abdominal aortic aneurysms. Cochrane Database Syst Rev 2012;9:CD009536. doi: 10.1002/14651858.
4. Golledge J, Norman PE, Murphy MP, Dalman RL. Challenges and opportunities in limiting abdominal aortic aneurysm growth. J Vasc Surg. 2017;65:225-233. doi: 10.1016/j.jvs.2016.08.003.
5. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: Pathogenesis and implications for management. Arterioscler Thromb Vasc Biol. 2006;26:2605-2613. doi: 10.1161/01.ATV.0000245819.32762.cb.
6. Ejiri J, Inoue N, Tsukube T, Munezane T, Hino Y, Kobayashi S, Hirata K, Kawashima S, Imajoh-Ohmi S, Hayashi Y, Yokozaki H, Okita Y, Yokoyama M. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: Protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res. 2003;59:988-996.
7. Tikellis C, Thomas MC. Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012;2012:256-294. doi: 10.1155/2012/256294.
8. Burrell LM, Johnston CI, Tikellis C, Cooper ME. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab. 2004;15:166-169. doi: 10.1016/j.tem.2004.03.001.
9. Chappel MC, Ferrario CM. ACE and ACE2: Their role to balance the expression of angiotensin II and angiotensin-(1-7). Kidney Int. 2006;70:8-10. doi: 10.1038/sj.ki.5000321.
10. Burrell LM, Harrap SB, Velkoska E, Patel SK. The ACE2 gene: Its potential as a functional candidate for cardiovascular disease. Clin Sci. 2013;124:65-76. doi: 10.1042/CS20120269.
11. Rentzsch B, Todiras M, Iliescu R, Popova E, Campos LA, Oliveira ML, Baltatu OC, Santos RA, Bader M. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension. 2008;52:967-973. doi: 10.1161/HYPERTENSIONAHA.108.114322.
12. Zhang C, Zhao YX, Zhang YH, et al. Angiotensin-converting enzyme 2 attenuates atherosclerotic lesions by targeting vascular cells. Proc Natl Acad Sci USA. 2010;107:15886-15891. doi: 10.1073/pnas.1001253107.
13. Thatcher SE, Zhang X, Howatt DA, Yiannikouris F, Gurley SB, Ennis T, Curci JA, Daugherty A, Cassis LA. Angiotensin-converting enzyme 2 decreases formation and severity of angiotensin II-induced abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol. 2014;34:2617-2623. doi: 10.1161/ATVBAHA.114.304613.
14. Singh N, Joshi S, Guo L, Baker MB, Li Y, Castellano RK, Raizada MK, Jarajapu YP. ACE2/Ang-(1-7)/Mas axis stimulates vascular repairrelevant functions of CD34+ cells. Am J Physiol Heart Circ Physiol. 2015;309:H1697-H1707. doi: 10.1152/ajpheart.00854.2014.
15. Hao Q, Dong X, Chen X, Yan F, Wang X, Shi H, Dong B. ACE2 inhibits angiotensin II-induced abdominal aortic aneurysm in mice [published online ahead of print January 31, 2017]. Hum Gene Ther. doi: 10.1089/hum.2016.144. https://www.ncbi.nlm.nih.gov/pubmed/28142259.
16. Kaneko H, Anzai T, Morisawa M, et al. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis. 2011;217:350-357. doi: 10.1016/j.atherosclerosis.2011.03.042.
17. Palmieri D, Pane B, Barisione C, Spinella G, Garibaldi S, Ghigliotti G, Brunelli C, Fulcheri E, Palombo D. Resveratrol counteracts systemic and local inflammation involved in early abdominal aortic aneurysm development. J Surg Res. 2011;171:e237-e246. doi: 10.1016/j.jss.2011.07.041.
18. Hibender S, Franken R, van Roomen C, Ter Braake A, van der Made I, Schermer EE, Gunst Q, van den Hoff MJ, Lutgens E, Pinto YM, Groenink M, Zwinderman AH, Mulder BJ, de Vries CJ, de Waard V. Resveratrol inhibits aortic root dilatation in the Fbn1C1039G/+ Marfan mouse model. Arterioscler Thromb Vasc Biol. 2016;36:1618-1626. doi: 10.1161/ATVBAHA.116.307841.
19. Oliveira Andrade JM, Paraíso AF, Garcia ZM, Ferreira AV, Sinisterra RD, Sousa FB, Guimarães AL, de Paula AM, Campagnole-Santos MJ, dos Santos RA, Santos SH. Cross talk between angiotensin-(1-7)/Mas axis and sirtuins in adipose tissue and metabolism of high-fat feed mice. Peptides. 2014;55:158-165. doi: 10.1016/j.peptides.2014.03.006.
20. Bonnefont-Rousselot D. Resveratrol and cardiovascular diseases. Nutrients 2016;8:250.
21. Zordoky BN, Robertson IM, Dyck JR. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta. 2015;1852:1155-1177. doi: 10.1016/j.bbadis.2014.10.016.
22. Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148:421-433. doi: 10.1016/j.cell.2012.01.017.
23. Clarke NE, Belyaev ND, Lambert DW, Turner AJ. Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress. Clin Sci. 2014;126:507-516. doi: 10.1042/CS20130291.
24. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, Tian B, Wagner T, Vatner SF, Sadoshima J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res. 2007;100:1512-1521. doi: 10.1161/01. RES.0000267723.65696.4a.
25. Biros E, Gäbel G, Moran CS, Schreurs C, Lindeman JH, Walker PJ, Nataatmadja M, West M, Holdt LM, Hinterseher I, Pilarsky C, Golledge J. Differential gene expression in human abdominal aortic aneurysm and aortic occlusive disease. Oncotarget. 2015;6:12984-12996. doi: 10.18632/oncotarget.3848.
26. Liao S, Curci JA, Kelley BJ, Sicard GA, Thompson RW. Accelerated replicative senescence of medial smooth muscle cells derived from abdominal aortic aneurysms compared to the adjacent inferior mesenteric artery. J Surg Res. 2000;92:85-95. doi: 10.1006/jsre.2000.5878.
27. Patel VB, Zhong JC, Fan D, Basu R, Morton JS, Parajuli N, McMurtry MS, Davidge ST, Kassiri Z, Oudit GY. Angiotensin-converting enzyme 2 is a critical determinant of angiotensin II-induced loss of vascular smooth muscle cells and adverse vascular remodeling. Hypertension. 2014;64:157-164. doi: 10.1161/HYPERTENSIONAHA.114.03388.
28. Thomas MC, Pickering RJ, Tsorotes D, Koitka A, Sheehy K, Bernardi S, Toffoli B, Nguyen-Huu TP, Head GA, Fu Y, Chin-Dusting J, Cooper ME, Tikellis C. Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse. Circ Res. 2010;107:888-897. doi: 10.1161/CIRCRESAHA.110.219279.
29. Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, Cooper ME, Thomas MC. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes. 2008;57:1018-1025. doi: 10.2337/db07-1212.
30. Mäki JM, Räsänen J, Tikkanen H, Sormunen R, Mäkikallio K, Kivirikko KI, Soininen R. Inactivation of the lysyl oxidase gene Lox leads to aortic aneurysms, cardiovascular dysfunction, and perinatal death in mice. Circulation. 2002;106:2503-2509.
31. Krishna SM, Seto SW, Jose RJ, Biros E, Moran CS, Wang Y, Clancy P, Golledge J. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol. 2015;35:389-398. doi: 10.1161/ATVBAHA.114.304732.
32. Moran CS, Jose RJ, Biros E, Golledge J. Osteoprotegerin deficiency limits angiotensin II-induced aortic dilatation and rupture in the apolipoprotein E-knockout mouse. Arterioscler Thromb Vasc Biol. 2014;34:2609-2616. doi: 10.1161/ATVBAHA.114.304587.
33. Koole D, Hurks R, Schoneveld A, Vink A, Golledge J, Moran CS, de Kleijn DP, van Herwaarden JA, de Vries JP, Laman JD, Huizinga R, Pasterkamp G, Moll FL. Osteoprotegerin is associated with aneurysm diameter and proteolysis in abdominal aortic aneurysm disease. Arterioscler Thromb Vasc Biol. 2012;32:1497-1504. doi: 10.1161/ATVBAHA.111.243592.
34. Patel SK, Velkoska E, Burrell LM. Emerging markers in cardiovascular disease: Where does angiotensin-converting enzyme 2 fit in Clin Exp Pharmacol Physiol. 2013;40:551-559. doi: 10.1111/1440-1681.12069.
35. Úri K, Fagyas M, Kertész A, Borbély A, Jenei C, Bene O, Csanádi Z, Paulus WJ, Édes I, Papp Z, Tóth A, Lizanecz E. Circulating ACE2 activity correlates with cardiovascular disease development. J Renin Angiotensin Aldosterone Syst. 2016;17. pii: 1470320316668435.
36. Lew RA, Warner FJ, Hanchapola I, Yarski MA, Ramchand J, Manohar J, Burrell LM, Smith AI. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol. 2008;93:685-693. doi: 10.1113/expphysiol.2007.040352.
37. Nie W, Wang Y, Yao K, Wang Z, Wu H. Serum angiotensin-converting enzyme 2 is an independent risk factor for in-hospital mortality following open surgical repair of ruptured abdominal aortic aneurysm. Exp Ther Med. 2016;12:1412-1418. doi: 10.3892/etm.2016.3466.
38. Castro-Chaves P, Cerqueira R, Pintalhao M, Leite-Moreira AF. New pathways of the renin-angiotensin system: The role of ACE2 in cardiovascular pathophysiology and therapy. Expert Opin Ther Targets. 2010;14:485-496. doi: 10.1517/14728221003709784.
39. Potente M, Ghaeni L, Baldessari D, Mostoslavsky R, Rossig L, Dequiedt F, Haendeler J, Mione M, Dejana E, Alt FW, Zeiher AM, Dimmeler S. SIRT1 controls endothelial angiogenic functions during vascular growth. Genes Dev. 2007;21:2644-2658. doi: 10.1101/gad.435107.
40. Gao P, Xu TT, Lu J, Li L, Xu J, Hao DL, Chen HZ, Liu DP. Overexpression of SIRT1 in vascular smooth muscle cells attenuates angiotensin II-induced vascular remodeling and hypertension in mice. J Mol Med. 2014;92:347-357. doi: 10.1007/s00109-013-1111-4.
41. Ma L, Li Y. SIRT1: Role in cardiovascular biology. Clin Chim Acta. 2015;440:8-15. doi: 10.1016/j.cca.2014.10.036.
42. Chen HZ, Wang F, Gao P, et al. Age-associated sirtuin 1 reduction in vascular smooth muscle links vascular senescence and inflammation to abdominal aortic aneurysm. Circ Res. 2016;119:1076-1088. doi: 10.1161/CIRCRESAHA.116.308895.
43. Zheng YH, Li FD, Tian C, Ren HL, Du J, Li HH. Notch-secretase inhibitor dibenzazepine attenuates angiotensin II-induced abdominal aortic aneurysm in ApoE knockout mice by multiple mechanisms. PLoS One. 2013;8:e83310. doi: 10.1371/journal.pone.0083310.
44. Ghosh A, Lu G, Su G, McEvoy B, Sadiq O, DiMusto PD, Laser A, Futchko JS, Henke PK, Eliason JL, Upchurch GR Jr. Phosphorylation of AKT and abdominal aortic aneurysm formation. Am J Pathol. 2014;184:148-158. doi: 10.1016/j.ajpath.2013.09.016.
45. Ghosh A, DiMusto PD, Ehrlichman LK, Sadiq O, McEvoy B, Futchko JS, Henke PK, Eliason JL, Upchurch GR Jr. The role of extracellular signalrelated kinase during abdominal aortic aneurysm formation. J Am Coll Surg. 2012;215:668-680.e1. doi: 10.1016/j.jamcollsurg.2012.06.414.
46. Jin HY, Song B, Oudit GY, Davidge ST, Yu HM, Jiang YY, Gao PJ, Zhu DL, Ning G, Kassiri Z, Penninger JM, Zhong JC. ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS One. 2012;7:e38502. doi: 10.1371/journal.pone.0038502.
47. Guo R, Li W, Liu B, Li S, Zhang B, Xu Y. Resveratrol protects vascular smooth muscle cells against high glucose-induced oxidative stress and cell proliferation in vitro. Med Sci Monit Basic Res. 2014;20:82-92. doi: 10.12659/MSMBR.890858.
48. Koole D, van Herwaarden JA, Schalkwijk CG, Lafeber FPJG, Vink A, Smeets MB, Pasterkamp G, Moll FL. A potential role for glycated crosslinks in abdominal aortic aneurysm disease. J Vasc Surg. 2017;65:1493-1503.e3. doi: 10.1016/j.jvs.2016.04.028.
49. Villard C, Eriksson P, Kronqvist M, Lengquist M, Jorns C, Hartman J, Roy J, Hultgren R. Differential expression of sex hormone receptors in abdominal aortic aneurysms. Maturitas. 2017;96:39-44. doi: 10.1016/j.maturitas.2016.11.005.
50. Emeto TI, Moxon JV, Biros E, Rush CM, Clancy P, Woodward L, Moran CS, Jose RJ, Nguyen T, Walker PJ, Golledge J. Urocortin 2 is associated with abdominal aortic aneurysm and mediates anti-proliferative effects on vascular smooth muscle cells via corticotrophin releasing factor receptor 2. Clin Sci. 2014;126:517-527. doi: 10.1042/CS20130425.
51. Biros E, Moran CS, Wang Y, Walker PJ, Cardinal J, Golledge J. microRNA profiling in patients with abdominal aortic aneurysms: The significance of miR-155. Clin Sci. 2014;126:795-803. doi: 10.1042/CS20130599.
52. Csiszar A, Labinskyy N, Pinto JT, Ballabh P, Zhang H, Losonczy G, Pearson K, de Cabo R, Pacher P, Zhang C, Ungvari Z. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol. 2009;297:H13-H20. doi: 10.1152/ajpheart.00368.2009.
53. Fraga-Silva RA, Costa-Fraga FP, Murca TM, et al. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension. 2013;61:1233-1238. doi: 10.1161/HYPERTENSIONAHA.111.00627.
54. Ailawadi G, Moehle CW, Pei H, Walton SP, Yang Z, Kron IL, Lau CL, Owens GK. Smooth muscle phenotypic modulation is an early event in aortic aneurysms. J Thorac Cardiovasc Surg. 2009;138:1392-1399. doi: 10.1016/j.jtcvs.2009.07.075.